7,805 results match your criteria: "Cambridge University Hospitals[Affiliation]"
Health Technol Assess
December 2024
Centre for Research in Public Health and Community Care, University of Hertfordshire, Hatfield, UK.
Eur J Vasc Endovasc Surg
December 2024
Cambridge Vascular Unit, Cambridge University Hospitals NHS Trust, Cambridge, UK.
Expert Rev Neurother
December 2024
Cambridge University Hospitals, Cambridge, UK.
Introduction: The seizures in Lennox-Gastaut syndrome are typically resistant to treatment. Seven antiseizure medications (ASMs) in the US (six in the UK/EU) are licensed for the treatment of seizures in LGS: lamotrigine, topiramate, rufinamide, clobazam, felbamate (not licensed in the UK/EU), cannabidiol and fenfluramine. Other options include neurostimulation, corpus callosotomy and dietary therapies, principally the ketogenic diet and its variants.
View Article and Find Full Text PDFDiabetes Ther
December 2024
School of Medicine, Keele University, Staffordshire, UK.
Introduction: We previously reported sex differences in the distribution of glycated haemoglobin (HbA1c) for men/women aged < 50 years vs older individuals, with implications for delayed diabetes diagnosis. Here, we explored whether this pattern was also seen in matched fasting plasma glucose (FPG) levels.
Methods: We extracted data on same-day, paired HbA1c and FPG levels from clinical biochemistry laboratory databases from Mersey and West Lancashire Teaching Hospitals NHS Trust (n = 10,153) and Cambridge University Hospitals NHS Foundation Trust (n = 10,022) between Jan 2019 and Dec 2023.
Stem Cells
December 2024
Department of Psychiatry, University of Oxford, Headington, Oxford OX3 7JX, UK.
Human induced pluripotent stem cells (iPSCs) provide powerful cellular models of Alzheimer's disease (AD) and offer many advantages over non-human models, including the potential to reflect variation in individual-specific pathophysiology and clinical symptoms. Previous studies have demonstrated that iPSC-neurons from individuals with Alzheimer's disease (AD) reflect clinical markers, including β-amyloid (Aβ) levels and synaptic vulnerability. However, despite neuronal loss being a key hallmark of AD pathology, many risk genes are predominantly expressed in glia, highlighting them as potential therapeutic targets.
View Article and Find Full Text PDFCochrane Database Syst Rev
December 2024
Department of Trauma & Orthopaedics, University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK.
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To determine the benefits and harms of injury prevention programmes on anterior cruciate ligament injuries.
View Article and Find Full Text PDFCurr Opin Neurol
December 2024
Department of Ophthalmology, Emory University School of Medicine.
Purpose Of Review: Leber hereditary optic neuropathy (LHON) is a mitochondrial DNA disease characterised by sequential bilateral vision loss due to loss of retinal ganglion cells. The purpose of this review is to provide an update on the results of recent clinical trials for LHON, focusing on studies of idebenone and lenadogene nolparvovec gene therapy.
Recent Findings: Evidence from three clinical studies (RHODOS, RHODOS-OFU, and LEROS) suggest that idebenone should be started early and continued for at least 24 months.
Importance: Limited studies have assessed the long-term benefit/risk of gene therapy for Leber hereditary optic neuropathy (LHON).
Objective: To determine the safety and efficacy of lenadogene nolparvovec in patients with LHON due to the MT-ND4 gene variant for up to 5 years after administration.
Design, Setting, And Participants: The RESCUE and REVERSE Long-Term Follow-up Study (RESTORE), conducted from 2018 to 2022, is the 5-year follow-up study of the 2 phase 3 clinical studies RESCUE (Efficacy Study of Lenadogene Nolparvovec for the Treatment of Vision Loss Up to 6 Months From Onset in LHON Due to the MT-ND4 Mutation) and REVERSE (Efficacy Study of Lenadogene Nolparvovec for the Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the MT-ND4 Mutation).
Cancer Discov
December 2024
Institute of Cancer Research, Sutton, Surrey, United Kingdom.
We profiled a large heterogenous cohort of matched diagnostic-relapse tumour tissue and paired plasma-derived cell free DNA (cfDNA) from patients with relapsed and progressive solid tumours of childhood. Tissue and cfDNA sequencing results were concordant, with a wider spectrum of mutant alleles and higher degree of intra-tumour heterogeneity captured by the latter, if sufficient circulating tumour-derived DNA (ctDNA) was present. Serial tumour sequencing identified putative drivers of relapse, with alterations in epigenetic drivers being a common feature.
View Article and Find Full Text PDFIJID Reg
December 2024
Department of Immunology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
•Recalcitrant warts affect immunocompetent and immunocompromised persons.•The optimal approach to refractory warts remains unclear.•Human papillomavirus vaccination is a promising therapy for recalcitrant warts.
View Article and Find Full Text PDFUrologia
December 2024
Department of Urology, Gemelli isola Tiberina Hospital, Rome, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction And Objective: Radical Cystectomy (RC) is one of the most common and complex surgical procedures in urologic surgery, and benign ureteroenteric anastomosis strictures (UAS) are complications described in about 15% of patients undergoing RC with different urinary diversion (UD). The aim of this study is to evaluate and analyze risk factors related to the development of ureteral stenosis after RC.
Materials And Methods: All consecutive patients who underwent RC with ileal conduit from December 2019 to December 2022 were included.
Neural Regen Res
December 2024
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
A large body of evidence has highlighted the role of non-coding RNAs in neurodevelopment and neuroinflammation. This evidence has led to increasing speculation that non-coding RNAs may be involved in the pathophysiological mechanisms underlying hydrocephalus, one of the most common neurological conditions worldwide. In this review, we first outline the basic concepts and incidence of hydrocephalus along with the limitations of existing treatments for this condition.
View Article and Find Full Text PDFRes Pract Thromb Haemost
November 2024
Hemocentro University of Campinas, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Background: Valoctocogene roxaparvovec, an adeno-associated virus-mediated gene therapy for severe hemophilia A, enables endogenous factor (F)VIII expression and provides bleed protection.
Objectives: Determine valoctocogene roxaparvovec durability, efficacy, and safety 4 years after treatment.
Methods: In the phase 3 GENEr8-1 trial, 134 adult male persons with severe hemophilia A without inhibitors and previously using FVIII prophylaxis received a 6 × 10 vg/kg infusion of valoctocogene roxaparvovec.
Adv Med Educ Pract
December 2024
Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK.
IPEM Transl
December 2024
Engineering Design Centre, Department of Engineering, University of Cambridge, Cambridge, CB2 1PZ, United Kingdom.
Acute healthcare providers operate large, diverse medical equipment inventories. Resources for managing these inventories is frequently scarce so must be prioritised such that maximum benefit is conferred per unit of expenditure. This review identifies publications which have discussed the clinical value conferred by mechanical ventilation (MV) and by extra corporeal membrane oxygenation (ECMO).
View Article and Find Full Text PDFJ Clin Med
December 2024
Department of Gynaecology, Division of Gynaecology, Poznan University of Medical Sciences, 61-701 Poznan, Poland.
This study aims to evaluate the prevalence of premenstrual syndrome (PMS) among Polish adolescents and explore its associations with mental health outcomes, lifestyle factors, and risk behaviours. Additionally, it seeks to examine the impact of PMS on quality of life, contributing to the foundation for initiatives that enhance adolescent menstrual health. This research is part of the POLKA 18 study, a youth-led cross-sectional survey conducted between April and December 2019.
View Article and Find Full Text PDFCancers (Basel)
November 2024
Department of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Background: There is no consensus regarding the indication for postoperative radiotherapy (PORT) for T1- and T2-classified squamous cell carcinoma (SCC) of the external auditory canal (EAC) even with negative surgical margins. This study aimed to evaluate whether PORT provides additional benefits for these cases.
Methods: We collected retrospective data from fourteen international hospitals, including resected pT1- and pT2-classified EAC SCC with negative surgical margins.
Clin Gastroenterol Hepatol
December 2024
Division of Gastroenterology, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. Electronic address:
Lancet Oncol
December 2024
Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Faculty of Health, Medicine, and Social Care, Anglia Ruskin University, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK. Electronic address:
Background: Procarbazine-containing chemotherapy regimens are associated with cytopenias and infertility, suggesting stem-cell toxicity. When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisolone (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity. We aimed to investigate the impact of this drug substitution on the mutation burden in stem cells, patient survival, and toxicity.
View Article and Find Full Text PDFRheumatology (Oxford)
December 2024
Rheumatology Department, Cambridge University Hospitals, Cambridge, United Kingdom.
Purpose: Oncoplastic breast-conserving surgery (OBCS) prevents compromise of breast aesthetics following large breast cancer excisions. This systematic review was conducted to investigate the outcomes (oncologic, surgical, cosmetic) of OBCS versus standard breast-conserving surgery (SBCS) and mastectomy post-neo-adjuvant systemic therapy.
Methods: Ovid, Web of Science, Cochrane, ClinicalTrials.
Nat Neurosci
December 2024
F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
Clin Microbiol Infect
December 2024
Department of Infectious Diseases, Hospital Clínico Universitario Zaragoza, Universidad de Zaragoza, IIS Aragón, CIBERINFEC, Zaragoza, Spain.
Genet Med Open
January 2024
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Purpose: Structural variants such as multiexon deletions and duplications are an important cause of disease but are often overlooked in standard exome/genome sequencing analysis. We aimed to evaluate the detection of copy-number variants (CNVs) from exome sequencing (ES) in comparison with genome-wide low-resolution and exon-resolution chromosomal microarrays (CMAs) and to characterize the properties of de novo CNVs in a large clinical cohort.
Methods: We performed CNV detection using ES of 9859 parent-offspring trios in the Deciphering Developmental Disorders (DDD) study and compared them with CNVs detected from exon-resolution array comparative genomic hybridization in 5197 probands from the DDD study.
Introduction: Treatment of pelvic organ prolapse (POP) is poorly understood in younger women as the majority of prolapse research is conducted in the older population. There is an urgent need to evaluate conservative POP treatments for management in younger women due to high surgical complications and reoperation rates.
Methods: Systematic review of the literature following PRISMA guidelines and registered in PROSPERO.